Virulite seeks suitor, FDA approval for new cold sore remedy

COSTA MESA, Calif. Virulite, a medical device manufacturer developing a new treatment for cold sores, is looking for a U.S. suitor, having retained Compass Point Capital and Murphy Business and Financial Corporation as its mergers and acquisitions advisors, the U.K. company announced Friday.

Virulite is presently in the process of obtaining Food and Drug Administration clearance for a portable, hand held device that uses an invisible, non-thermal band of near-infrared light that, according to the company, reduces the healing time of cold cores by up to one half.

The company completed a U.S. market test of the product through Walgreens’ online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline, Virulite reported.